895 related articles for article (PubMed ID: 30188791)
1. Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
Kolesar JM; Liu G
J Clin Oncol; 2018 Oct; 36(30):3065-3066. PubMed ID: 30188791
[No Abstract] [Full Text] [Related]
2. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
Szmulewitz RZ; Stadler WM; Ratain MJ
J Clin Oncol; 2018 Oct; 36(30):3064-3065. PubMed ID: 30188784
[No Abstract] [Full Text] [Related]
3. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Rescigno P; de Bono JS
Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
[No Abstract] [Full Text] [Related]
4. Reply to L. Dirix, B. De Laere et al, and A. Sharp et al.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Scher HI; Antonarakis ES; George DJ
J Clin Oncol; 2019 Aug; 37(24):2184-2186. PubMed ID: 31265357
[No Abstract] [Full Text] [Related]
5. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
van Soest RJ; de Wit R; van Weerden WM
Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
[No Abstract] [Full Text] [Related]
6. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
O'Cathail M; Sundar S
Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
[No Abstract] [Full Text] [Related]
7. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
Conteduca V; Lolli C; De Giorgi U
Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
[No Abstract] [Full Text] [Related]
8. Reply to M.A.N. Şendur et al and J. Michels.
Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
J Clin Oncol; 2017 Jan; 35(1):123. PubMed ID: 28034066
[No Abstract] [Full Text] [Related]
9. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
[No Abstract] [Full Text] [Related]
10. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono J
Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
[No Abstract] [Full Text] [Related]
11. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
[No Abstract] [Full Text] [Related]
12. Reply to M. Horiguchi et al.
Eisenberger MA; Zhang W; Shun Z; de Bono J
J Clin Oncol; 2018 Mar; 36(8):826-827. PubMed ID: 29373098
[No Abstract] [Full Text] [Related]
13. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono JS
Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
[No Abstract] [Full Text] [Related]
14. Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
Xu S; De Porre P
Clin Pharmacokinet; 2017 Feb; 56(2):213-214. PubMed ID: 27815867
[No Abstract] [Full Text] [Related]
15. In reply.
Auchus RJ; Yu MK; Nguyen S; Mundle SD
Oncologist; 2015 May; 20(5):e14. PubMed ID: 25888269
[TBL] [Abstract][Full Text] [Related]
16. Reply to A. Addeo and A. Bahl.
Scher HI; Heller G; Molina A; Kheoh T; de Bono JS
J Clin Oncol; 2016 Feb; 34(4):387-8. PubMed ID: 26598756
[No Abstract] [Full Text] [Related]
17. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
Shiota M; Yokomizo A
Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
[No Abstract] [Full Text] [Related]
18. Low-Dose Abiraterone With Food: Rebutting an Editorial.
Szmulewitz RZ; Karrison T; Stadler WM; Ratain MJ
J Clin Oncol; 2018 Oct; 36(30):3060-3061. PubMed ID: 30188785
[No Abstract] [Full Text] [Related]
19. Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate.
Woei-A-Jin FJSH; Van Nieuwenhuyse T; van Erp NP; Beuselinck B; Stroobants S; Moes DJAR; Osanto S; Spriet I
J Clin Oncol; 2018 Oct; 36(30):3062-3064. PubMed ID: 30188790
[No Abstract] [Full Text] [Related]
20. Low-Fat Abiraterone Food Effect Is of Great Consequence.
Tannock IF
J Clin Oncol; 2018 Oct; 36(30):3058-3059. PubMed ID: 30188783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
